Last Updated on July 29, 2021 by Nancy Carteron, MD, FACR
1 out of 3 People with HIV have Hep C
When a person is infected with two or more different viruses, it is called a coinfection.
Infection with the hepatitis C virus (HCV or hep C for short) is the most common coinfection in people with the human immunodeficiency virus (HIV).
Complications of an HIV & hep C coinfection has become an increasingly important medical issue. As improvements in HIV treatment have reduced the number of deaths due to the human immunodeficiency virus and opportunistic illnesses, liver disease has become the leading cause of hospitalization and death in people with HIV/AIDS.
It is estimated that about 1 million people in the U.S. are infected with the human immunodeficiency virus and approximately 4 million are infected with hep C. As many as 300,000 people with HIV may also be coinfected with hepatitis C.
HIV & Hep C Coinfection
The human immunodeficiency virus and hep C have similar blood-to-blood transmission routes.
Because both the human immunodeficiency virus and hep C are transmitted through sharing of needles and works, many injection drug users get both diseases – in some groups of injection drug users, the rate of coinfection is as high as 90% (or 9 out of 10 people). In addition, a significant number of people who have received blood transfusions before blood donations were tested for the human immunodeficiency virus and hep C are also coinfected.
STI Masterclass: Breaking Through the Fear, Shame, and Stigma of an STI Diagnosis
If you’re fed up with feeling unworthy, less-than, damaged, or limited by your STI, then join the next cohort in the 60-Day Masterclass, and leave feeling empowered, knowledgable, and confident again!
Click Here to Learn More
Though hep C is less likely than HIV to be transmitted sexually or from mother-to-baby during pregnancy, some studies have shown that the risk of sexual or mother-to-baby hep C transmission is greater if a person also has the human immunodeficiency virus.
With the introduction of newer medications to treat the human immunodeficiency virus, people are living longer only to be faced with hep C-related liver disease. As a result, liver disease is now a leading cause of death in people co-infected with HIV and hep C.
Compared to people without the human immunodeficiency virus, coinfected people have a greater risk and faster progression of their liver disease.
In fact, people who are coinfected are at a greater risk of developing severe liver damage – more than 2 or 3 times as fast as for someone who has hep C alone. It is hard to predict at what rate your liver disease will progress, but in a recent study, 1 out of 4 patients progressed from mild to significant liver scarring in less than 3 years.
The good news is that you can do something about the damage hep C is doing to your liver!
The way that hep C affects HIV disease is not as clear, but people with hep C may have a higher chance of liver-related problems due to the drugs used to treat the human immunodeficiency virus. Some people may even have to stop taking or change their HIV drugs because of the damage some of these medications can cause to the liver; this is why it is so important that you keep your liver as healthy as possible.
The Liver
Did you know that the average time it takes for people with the human immunodeficiency virus and hep C to progress with cirrhosis (massive scarring of the liver) is 7 years?
The liver is the largest organ in the body.
It is called a “non-complaining organ” since it can be damaged and a person might not even know it.
One of the most important functions that the liver performs is that it filters – what people eat, breathe, and substances that get on the skin. The liver processes HIV medicines, so it is important that people with the human immunodeficiency virus keep their livers healthy.
If hepatitis C causes enough damage to the liver, it may not be possible to start or stay on your HIV medications.
Alcohol can also cause liver damage, so it is important that someone with hep C reduce or stop drinking alcohol.
Finally, there are medications (vaccines) to protect you from hepatitis viruses that are recommended for people with HIV and hep C. However, there is NO vaccine for hep C.
Hep C in People with HIV
People with the human immunodeficiency virus who have been diagnosed with hep C should be evaluated by a healthcare provider who specializes in these diseases.
Talking to a healthcare provider about hep C in someone with HIV is more urgent than in someone with hep C alone since the rate of liver disease progression is faster. It is best to begin conversation with your doctor about maintaining liver health before hep C can do further damage.
Support groups can be very helpful for people coinfected with HIV and hepatitis C, especially when dealing with the emotional issues of managing, treating, and living with these two chronic, and potentially life-threatening diseases.
The STI Project is attending The Viral Hepatitis Summit this fall and will have up-to-date information to relay to our readers as well!
- HIV/AIDS Support Groups
- Hepatitis Support Groups
- HIV/AIDS Resources
- Hepatitis Information & Personal Perspectives
- Resources & Perspectives About HIV
- External HIV & Hep C References
- Would you like to share your story?
References
- Symptoms
- Vestergaard, Hanne Thang, et al. “Transfusion transmission of hepatitis A virus with fecal shedding in a previously hepatitis A vaccinated recipient.” Journal of infection and chemotherapy 24.9 (2018): 766-768.
- Parsa Nahad, Mehdi, et al. “Seroprevalence of Hepatitis E Virus Infection among Patients with Acute Hepatitis Symptoms in Ahvaz, Iran.” International Journal of Medical Laboratory 5.1 (2018): 11-18.
- Brietzke, Aline P., et al. “Neuroplastic effects of transcranial direct current stimulation on painful symptoms reduction in chronic hepatitis C: a phase II randomized, double blind, sham controlled trial.” Frontiers in neuroscience 9 (2016): 498.
- Evon, Donna M., et al. “Patient-reported symptoms during and after direct acting antiviral therapies for chronic hepatitis C: The PROP UP Study.” Journal of hepatology (2019).
- Kirstein, Martha M., Arndt Vogel, and Michael P. Manns. “Autoimmune Hepatitis.” Evidence‐based Gastroenterology and Hepatology 4e (2019): 592-601.
- Testing
- Easterbrook, Philippa, et al. “HIV and hepatitis testing: global progress, challenges, and future directions.” AIDS Rev 18.1 (2016): 3-14.
- Bottero, Julie, et al. “2014 French guidelines for hepatitis B and C screening: a combined targeted and mass testing strategy of chronic viruses namely HBV, HCV and HIV.” Liver International 36.10 (2016): 1442-1449.
- Coffie, Patrick A., et al. “Trends in hepatitis B virus testing practices and management in HIV clinics across sub-Saharan Africa.” BMC infectious diseases 17.1 (2017): 706.
- AASLD/IDSA HCV Guidance Panel, et al. “Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.” Hepatology 62.3 (2015): 932-954.
- Mezzo, Jennifer L., et al. “The Hepatitis Testing and Linkage-to-Care Data Review Process: An Approach to Ensuring the Quality of Program Data.” Public Health Reports 131.2_suppl (2016): 44-48.
- Treatment
- Terrault, Norah A., et al. “A ASLD guidelines for treatment of chronic hepatitis B.” Hepatology 63.1 (2016): 261-283.
- European Association for The Study of The Liver. “EASL recommendations on treatment of hepatitis C 2018.” Journal of hepatology 69.2 (2018): 461-511.
- Terrault, Norah A., et al. “Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.” Hepatology 67.4 (2018): 1560-1599.
- Charlton, Michael, et al. “Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.” Gastroenterology 148.1 (2015): 108-117.
- World Health Organization. Guidelines for the Prevention Care and Treatment of Persons with Chronic Hepatitis B Infection: Mar-15. World Health Organization, 2015.
- Prevention
- Centers for Disease Control and Prevention. “HIV and viral hepatitis.” South Carolina State Documents Depository (2017).
- Zhang, Qian, et al. “Epidemiology of hepatitis B and hepatitis C infections and benefits of programs for hepatitis prevention in northeastern China: a cross-sectional study.” Clinical Infectious Diseases 62.3 (2015): 305-312.
- Tavitian, Suzanne, et al. “Ribavirin for chronic hepatitis prevention among patients with hematologic malignancies.” Emerging infectious diseases 21.8 (2015): 1466.
- Dahiya, Parveen, et al. ““Hepatitis”–Prevention and management in dental practice.” Journal of education and health promotion 4 (2015).
- He, Tianhua, et al. “Prevention of hepatitis C by screening and treatment in US prisons.” Annals of internal medicine 164.2 (2016): 84-92.
- Transmission
- Pan, Calvin Q., et al. “Tenofovir to prevent hepatitis B transmission in mothers with high viral load.” New England Journal of Medicine 374.24 (2016): 2324-2334.
- Doceul, Virginie, et al. “Zoonotic hepatitis E virus: Classification, animal reservoirs and transmission routes.” Viruses 8.10 (2016): 270.
- Jourdain, Gonzague, et al. “Tenofovir versus placebo to prevent perinatal transmission of hepatitis B.” New England Journal of Medicine 378.10 (2018): 911-923.
- Hofmeister, Megan G., Monique A. Foster, and Eyasu H. Teshale. “Epidemiology and transmission of hepatitis A virus and hepatitis E virus infections in the United States.” Cold Spring Harbor perspectives in medicine 9.4 (2019): a033431.
- Dionne-Odom, Jodie, et al. “# 38: Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission.” American journal of obstetrics and gynecology 214.1 (2016): 6-14.
References
- Symptoms
- Earnshaw, Valerie A., et al. “HIV stigma and physical health symptoms: Do social support, adaptive coping, and/or identity centrality act as resilience resources?.” AIDS and Behavior 19.1 (2015): 41-49.
- Lyon, Maureen E., et al. “Advance care planning and HIV symptoms in adolescence.” Pediatrics 142.5 (2018): e20173869.
- Garey, Lorra, et al. “Anxiety, depression, and HIV symptoms among persons living with HIV/AIDS: the role of hazardous drinking.” AIDS care 27.1 (2015): 80-85.
- Webel, Allison R., et al. “A cross-sectional relationship between social capital, self-compassion, and perceived HIV symptoms.” Journal of pain and symptom management 50.1 (2015): 59-68.
- Braksmajer, Amy, et al. “Effects of Discrimination on HIV-Related Symptoms in Heterosexual Men of Color.” American journal of men’s health 12.6 (2018): 1855-1863.
- Testing
- World Health Organization. Guidelines on HIV self-testing and partner notification: supplement to consolidated guidelines on HIV testing services. World Health Organization, 2016.
- Arya, Monisha, et al. “The Promise of Patient-Centered Text Messages for Encouraging HIV Testing in an Underserved Population.” The Journal of the Association of Nurses in AIDS Care: JANAC 29.1 (2018): 101-106.
- Greensides, Dawn R., et al. “Alternative HIV testing methods among populations at high risk for HIV infection.” Public health reports (2016).
- Granich, Reuben M., et al. “Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model.” The Lancet 373.9657 (2009): 48-57.
- Kalichman, Seth C., and Leickness C. Simbayi. “HIV testing attitudes, AIDS stigma, and voluntary HIV counselling and testing in a black township in Cape Town, South Africa.” Sexually transmitted infections 79.6 (2003): 442-447.
- Treatment
- Cihlar, Tomas, and Marshall Fordyce. “Current status and prospects of HIV treatment.” Current opinion in virology 18 (2016): 50-56.
- Gonzalez, Jeffrey S., et al. “Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis.” Journal of acquired immune deficiency syndromes (1999) 58.2 (2011).
- Callaghan, Mike, Nathan Ford, and Helen Schneider. “A systematic review of task-shifting for HIV treatment and care in Africa.” Human resources for health 8.1 (2010): 8.
- Benjamin, Laura A., et al. “HIV, antiretroviral treatment, hypertension, and stroke in Malawian adults: a case-control study.” Neurology 86.4 (2016): 324-333.
- Levi, Jacob, et al. “Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades.” BMJ global health 1.2 (2016): e000010.
- Prevention
- Cohen, Myron S., et al. “Antiretroviral therapy for the prevention of HIV-1 transmission.” New England Journal of Medicine 375.9 (2016): 830-839.
- World Health Organization. Policy brief: Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. No. WHO/HIV/2017.05. World Health Organization, 2017.
- Baeten, Jared M., et al. “Use of a vaginal ring containing dapivirine for HIV-1 prevention in women.” New England Journal of Medicine 375.22 (2016): 2121-2132.
- Fowler, Mary G., et al. “Benefits and risks of antiretroviral therapy for perinatal HIV prevention.” New England Journal of Medicine 375.18 (2016): 1726-1737.
- World Health Organization. “Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations–2016 update.” (2016).
- Transmission
- Rodger, Alison J., et al. “Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy.” Jama 316.2 (2016): 171-181.
- Landefeld, C. C., et al. “Prevention of Mother-to-Child Transmission of HIV in Yaounde: Barrier to Care.” AIDS care 30.1 (2018): 116-120.
- Zafer, Maryam, et al. “Effectiveness of semen washing to prevent human immunodeficiency virus (HIV) transmission and assist pregnancy in HIV-discordant couples: a systematic review and meta-analysis.” Fertility and sterility 105.3 (2016): 645-655.
- Cohen, Myron S., et al. “Antiretroviral therapy for the prevention of HIV-1 transmission.” New England Journal of Medicine 375.9 (2016): 830-839.
- Poon, Art FY, et al. “Near real-time monitoring of HIV transmission hotspots from routine HIV genotyping: an implementation case study.” The lancet HIV 3.5 (2016): e231-e238.